Holen Sie sich die Stockscreener-App
8.63
11.03%
-1.07
Handel nachbörslich:
8.41
-0.22
-2.55%
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Replimune Group Inc (REPL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Replimune Group Market Sentiment - Benzinga España
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
REPL|Replimune Group Inc|Price:9.700|Chg%:-0.760 - TradingKey
Replimune Group Inc (REPL) Institutional Confidence - TradingKey
Replimune Group Inc (REPL) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Replimune Group Inc (REPL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
REPL|Replimune Group Inc|Price:9.695|Chg%:-0.765 - TradingKey
Replimune Group Inc (REPL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Replimune Group (REPL) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsin - The National Law Review
Replimune Group, Inc. Revenue Breakdown – NASDAQ:REPL - TradingView
Replimune Group Inc (REPL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Replimune stock trades lower after cash burn and clinical updates shape outlook - Ad-hoc-news.de
Replimune's RP1 Drug Probably Works, But It's Not A Buy Yet (NASDAQ:REPL) - Seeking Alpha
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
Replimune stock gains after updated RP1 data and cash runway outlook - AD HOC NEWS
ETFs Investing in Replimune Group, Inc. Stocks - TradingView
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
BMO Capital downgrades Replimune Group (REPL) - MSN
Liquidity Mapping Around (REPL) Price Events - Stock Traders Daily
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL) - GlobeNewswire
Form PRE 14A REPLIMUNE GROUP For: 13 July By Investing.com - Investing.com Nigeria
Price to earnings forward of Replimune Group, Inc. – MUN:7R8 - TradingView
Replimune Group (NASDAQ: REPL) seeks approval to double authorized stock - Stock Titan
Replimune Group (REPL) Q4 2026 earnings summary - Quartr
Replimune soars after FDA reconsiders denial of cancer drug - MSN
symbol__ Stock Quote Price and Forecast - CNN
Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
9 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug - Stocktwits
Replimune Group stock and its cancer immunotherapy pipeline - Ad-hoc-news.de
3 Biotech Stocks to Watch Before Wall Street Catches On - TradingView
Replimune Group Inc. (REPL) Holds Gains Near Resistance as Support HoldsDelta Hedging - DonanımHaber
The week in pharma: action, reaction and insight – week to July 3, 2026 - The Pharma Letter
Replimune says FDA rejected its lead drug for skin cancer - MSN
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
REPL Maintains Neutral Rating by Wedbush -- Price Target Raised to $9.00 - GuruFocus
Replimune: Stock Buoyant On Third Try At RP1 ApprovalFDA AdCom May Be Crucial (REPL) - Seeking Alpha
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):